ID: ALA203209

Max Phase: Preclinical

Molecular Formula: C23H21NO3S

Molecular Weight: 391.49

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCC(C)c1csc2nc(O)c(-c3cccc(Oc4ccccc4)c3)c(O)c12

Standard InChI:  InChI=1S/C23H21NO3S/c1-3-14(2)18-13-28-23-20(18)21(25)19(22(26)24-23)15-8-7-11-17(12-15)27-16-9-5-4-6-10-16/h4-14H,3H2,1-2H3,(H2,24,25,26)

Standard InChI Key:  CWXWIWQFHCZDQW-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 391.49

Molecular Weight (Monoisotopic): 391.1242

AlogP: 6.68

#Rotatable Bonds: 5

Polar Surface Area: 62.58

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 9.55

CX Basic pKa:

CX LogP: 6.82

CX LogD: 6.82

Aromatic Rings: 4

Heavy Atoms: 28

QED Weighted: 0.40

Np Likeness Score: -0.54

References

1. Buchstaller HP, Siebert CD, Steinmetz R, Frank I, Berger ML, Gottschlich R, Leibrock J, Krug M, Steinhilber D, Noe CR..  (2006)  Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor.,  49  (3): [PMID:16451052] [10.1021/jm0503493]

Source

Source(1):

• Scientific Literature